Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-000184 vs TDF in Chronic Hepatitis B Virus Infection (B-SUPREME)
NCT06963710Phase 2Active, not recruiting
- Sponsor
- Aligos Therapeutics
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Countries
- 14
01
Overview
A Phase 2 trial of pevifoscorvir in hepatitis B infection (HBV), sponsored by Aligos Therapeutics. Started Jul 2025; status: active, not recruiting.
02
Drugs
pevifoscorvir
03
Conditions
hepatitis B infection (HBV)
Beyond the preview
Go deeper on NCT06963710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963710.